4.7 Article

Partial enteral nutrition has no benefit on bone health but improves growth in paediatric patients with quiescent or mild Crohn's disease

Journal

CLINICAL NUTRITION
Volume 39, Issue 12, Pages 3786-3796

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.clnu.2020.04.012

Keywords

Paediatric inflammatory bowel disease; Enteral nutrition; Bone and muscle geometry; Microbiome; Metabolome

Funding

  1. ECCO-Nestle Health Science Nutrition Fellowship 2015 - Nestle Health Science Nutrition
  2. National Scholarship Program of the Slovak Republic
  3. Collegium Talentum
  4. SPP Foundation
  5. Ministry of Education of the Slovak Republics [VEGA1/1267/12]
  6. Ludwig-Maximilians-University Munich [FoFoLe 968/2017, FoFoLe 742]
  7. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [395357507 - SFB 1371]
  8. European Commission [289346, 633595, 733206]
  9. European Research Council [META-GROWTH ERC2012-AdGeno.322605]
  10. German Research Council [INST 409/224-1 FUGG]

Ask authors/readers for more resources

Background and aims: Exclusive enteral nutrition induces remission, improves bone health and growth in paediatric Crohn's disease (CD) patients, but is highly demanding for patients. We investigated efficacy of partial enteral nutrition (PEN) on bone health, growth and course in CD patients and assessed microbial and metabolic changes induced by PEN. Methods: We performed a two centre, non-randomized controlled intervention study in quiescent CD patients aged <19 years. Patients in intervention group received a liquid formula providing similar to 25% of daily energy for one year. At baseline, after 3, 6, 9 and 12 months, we collected data on bone, muscle (peripheral quantitative computertomography), anthropometry, disease activity (weighted paediatric CD activity index), metabolomic profile (liquid chromatography mass spectrometry), and faecal microbiome (16S rRNA gene sequencing). Results: Of 41 CD patients, 22 received the intervention (PEN) (mean age 15.0 +/- 1.9 years, 50% male), 19 served as controls (non-PEN) (12.8 +/- 3.1 years, 58% male). At baseline, mean bone quality was comparable to reference population with no improvement during the intervention. Relapse rate was low (8/41, PEN 4/22 and non-PEN 4/19, ns). PEN was not associated with microbiota community changes (beta diversity) but significantly reduced species diversity. Metabolome changes with upregulation of phosphatidylcholines in PEN patients are likely related to lipid and fatty acid composition of the formula. PEN significantly improved growth in a subgroup with Tanner stage 1-3. Conclusion: In our cohort of paediatric CD patients, PEN did not affect bone health but improved growth in patients with a potential to grow. (C) 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available